IONS — what changed in the latest 10-Q
A section-by-section comparison of IONS's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-07-29 vs the prior 10-Q · 2026-04-29
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +21 | −18 | ~37 | 48 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 2 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 2 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | Text added/removed | +2 | −4 | ~31 | 176 |
| Other information | Text added/removed | +1 | −4 | ~1 | 3 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-07-29
SPINRAZA is an antisense medicine for the treatment of patients with spinal muscular atrophy, or SMA, a progressive, debilitating and often fatal genetic disease. Higher dose SPINRAZA was approved and launched in the U.S. and EU for the treatment of SMA. Higher dose SPINRAZA is also approved in Japa…
WAINUA (WAINZUA in Europe) is a once monthly, self-administered subcutaneous LICA medicine that is approved in numerous countries, including the U.S., EU, UK, Canada and China, for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis, or ATTRv-PN, a debilitati…
Zilganersen is our investigational medicine for AxD. The FDA has granted Priority Review of zilganersen, with a Prescription Drug User Fee Act, or PDUFA, action date of September 22, 2026. The regulatory submission was based on the positive results from the Phase 3 portion of the pivotal study in ch…
Obudanersen is our medicine in development for AS. In July 2026, we completed enrollment of the Phase 3 study, REVEAL, which we designed to evaluate the efficacy and safety of obudanersen. In addition, we are continuing to conduct the open label Phase 1/2 study, HALOS, of obudanersen in patients wit…
Bepirovirsen is our medicine in development for chronic hepatitis B, or CHB. GSK is developing bepirovirsen. The FDA has granted Priority Review of bepirovirsen, with a PDUFA action date of October 26, 2026. In May 2026, GSK presented positive Phase 3 data for bepirovirsen at the 2026 European Assoc…
Text removed vs the prior filing · source: 10-Q · 2026-04-29
WAINUA (WAINZUA in Europe) is a once monthly, self-administered subcutaneous LICA medicine that is approved in numerous countries, including the U.S., EU, UK, Canada and China, for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis, or ATTRv-PN, a debilitati…
SPINRAZA is an antisense medicine for the treatment of patients with spinal muscular atrophy, or SMA, a progressive, debilitating and often fatal genetic disease. Higher dose SPINRAZA was approved and launched in the U.S. and EU for the treatment of SMA. Higher dose SPINRAZA is also approved in Japa…
Olezarsen is our investigational medicine currently under regulatory review for sHTG, a second potential indication with a broad patient population. The FDA has granted Priority Review of olezarsen, with a Prescription Drug User Fee Act, or PDUFA, action date of June 30, 2026. In March 2026, the Eur…
Zilganersen is our investigational medicine for AxD. The FDA has granted Priority Review of zilganersen, with a PDUFA action date of September 22, 2026. The regulatory submission was based on the positive results from the Phase 3 portion of the pivotal study in children and adults with AxD. These re…
Obudanersen is our medicine in development for AS. In June 2025, we initiated the Phase 3 study, REVEAL, which we designed to evaluate the efficacy and safety of obudanersen. In addition, we are continuing to conduct the open label Phase 1/2 study, HALOS, of obudanersen in patients with AS designed …
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-07-29
● WAINUA faces competition from numerous competitors, including an oral product in markets outside the U.S.;
In December 2021, we entered into a collaborative agreement with AstraZeneca under which we granted AstraZeneca exclusive worldwide rights to develop and commercialize WAINUA, with the parties sharing responsibility and costs for development and U.S. commercialization activities, and AstraZeneca ass…
Text removed vs the prior filing · source: 10-Q · 2026-04-29
● WAINUA faces competition in ATTRv-PN from numerous competitors, including an oral product, and, if approved for ATTR-CM, would face competition from several commercial competitors, including an oral product, and could face competition from additional commercial competitors in the future;
We have entered into a collaborative arrangement with AstraZeneca to develop and commercialize WAINUA. Under the terms of the collaboration agreement, we and AstraZeneca are co-developing and co-commercializing WAINUA in the U.S. and AstraZeneca has the sole right to commercialize WAINUA in all othe…
In addition, a Joint Steering Committee, or JSC, having equal membership from us and AstraZeneca, and various subcommittees oversee and coordinate the development, manufacturing, commercialization and other exploitation activities for WAINUA in the U.S. by mutual agreement. If any subcommittee canno…
● AstraZeneca for the joint development and funding of WAINUA;
Other information
Text added vs the prior filing · source: 10-Q · 2026-07-29
Shannon Devers Executive Vice President, Chief Human Resources Officer Termination April 14, 2026 X Indeterminable, as number of shares to be sold is dependent on total number of shares released upon vesting The earlier to occur of (i) April 4, 2027, and (ii) Upon the execution of all instructions p…
Text removed vs the prior filing · source: 10-Q · 2026-04-29
Eric Swayze Executive Vice President, Research Termination March 6, 2026 X 177,770 The earlier to occur of (i) December 31, 2027, and (ii) Upon the execution of all instructions provided in the plan
Holly Kordasiewicz Executive Vice President, Chief Development Officer Adoption March 13, 2026 X Indeterminable, as number of shares to be sold is dependent on total number of shares released upon vesting The earlier to occur of (i) May 31, 2027, and (ii) Upon the execution of all instructions provi…
Eric Swayze Executive Vice President, Research Adoption March 6, 2026 X Indeterminable, as number of shares to be sold is dependent on total number of shares released upon vesting The earlier to occur of (i) December 31, 2030, and (ii) Upon the execution of all instructions provided in the plan
Frank Bennett Executive Vice President, Chief Scientific Officer Adoption March 31, 2026 X 67,386 The earlier to occur of (i) July 5, 2027, and (ii) Upon the execution of all instructions provided in the plan
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice